Introduction
Fluorescence molecular imaging is an indispensable tool in the fields of biology and life sciences. [1] In conventional fluorescence microscopes, the sensitivity of opticald etection is limited to the visible region (l = 400-700 nm). [2] Thus, visible-emitting, fluorescent probes are usually used for fluorescence molecular imaging in vitro (at the cellular level). [1b] However, visible-emitting probesare not suitable for whole-body fluorescence imaging because of the strong absorption and scattering of visible light by blooda nd tissues. [3] Compared to visible light, near-infrared (NIR) light over l = 700 nm is highly permeable in living tissues. [3] Thus, NIR-emitting fluorescent probes are used for deep-tissue imaging at the whole-body level [4] To achieve in vitro and in vivo moleculari maging by using single fluorescent probes, probes that have dual-color emissions from the visible region to the NIR region are desirable.
Recently,s everal reports have appeared on visible-and NIRemitting dual-colorp robes [5] for fluorescencei maging. Kwon et al. developed dual-color-emitting (l = 450-850 nm) upconversion nanocapsules for different cancerb ioimaging in vitro and in vivo. [5d] They modifiedn anocapsule probesw ith the anti-MUC1a ntibody or TCP1 peptide form olecular imagingo f cancer cells. Zhang et al. developed InP/ZnSe/ZnS quantum dot (QD)-based probes with strong visible and NIR emission (l = 550-1000 nm) fori nv itro and in vivo tumor imaging, for which the QD probe was functionalized with the cRGD peptide. [5f] More recently,M ae tal. reportedafluorescent unimolecular micelle probe for in vitro and in vivo cancer imaging; the micelle probe included different types of organic fluorescent dyes having dual emission in the visible and NIR regions (l = 500-750 nm). [5g] In previous work, we developedf luorescent recombinant protein capped PbS QDs that showedd ual emissiona tl = 515 and 1100 nm. [5c] We used ar ecombinant protein (GST-EGFP-GB1;G ST = glutathione s-transferase, EGFP = enhanced green fluorescent protein, GB1 = immunoglobulin bindingd omain of protein G) as ap rotectingr eagent to prepareP bS QDsw ithd ual-color emissionr esulting from EGFP and QDs. Although GST-EGFP-GB1-capped PbS QDs are useful for dual-color moleculari maging, this probe cannot be applied in the conventionalNIR-wavelength region (l = 700-900nm).
The objective of this work was to develop ad ual-color (visible-and NIR)-emitting QD probe that could be used forc onventional fluorescencem icroscopes and in vivo imaging instruments (spectral response: l = 400-900 nm). Fluorescence molecular imaging of specific cancerc ellsi sc rucial fort umor detection and diagnosis. For cancer-cell-targeted imaging, antibodies, peptides, carbohydrates, and ligands towards surface receptors have been used for the functionalization of QDs. [6] Amongs uch QD probes, monoclonal-antibody-functionalized probesa re highly specific towards membrane receptors such as epidermal growth factor receptors (EGFRs) on cancer cells. [7] Near-infrared (NIR)-emitting fluorescent probesa re widely used for molecular imaginga tt he whole-body level.H owever,N IRemitting fluorescent probes emitting over l = 700 nm are not suitable for moleculari maging at the cellular level, because most of the conventional fluorescence microscopesh ave very low opticals ensitivity in the NIR region. Thus, to achievef luorescence imaging at the cellular and whole-body levels by using single probes, visible and NIR-emitting dual-color fluorescent probes are desirable. For dual-colorf luorescencem olecular imaging, we synthesized fluorescent, recombinant-proteinconjugated, NIR-emitting quantum dots (QDs),i nw hich the recombinant protein consists of enhanced green fluorescent protein (EGFP) and the immunoglobulinb inding domain (B1) of protein G. This dual-color fluorescent QD probe binds the Fc region of immunoglobulinG (IgG) through its B1 domain at the QD surface and acts as am olecular-imaging probe at both the cellular and whole-bodyl evels.I nt his paper,w ep resent the synthesis of fluorescent, recombinant protein (HisEGFP-GB1)-conjugated, NIR-emitting QDsa nd their application to the dual-color molecular imaging of breast cancer cells in vitro and in vivo.
To date,f or the preparation of antibody-functionalized QDs, cross-coupling reactions have typically been used to conjugate the antibodyt ot he QDs, and the antibody molecules bind to the functional groups, such as the carboxyl anda mino groups, at the surface of the QDs. [8] However,t his conjugation method results in nonspecific binding of the antibody to the QDs, which leads to aggregation of the QDs and lowers the activity of the antibody. [9] To overcomet his disadvantage, adaptor proteins such as streptavidin and protein A/G have been used for the functionalizationo fQ Ds with antibodies. [5c, 10] Recently,w er eported that as malla daptor protein, immunoglobulin binding domain (B1), [11] could be used to mediate antibody conjugation for the preparation of antibody-functionalized QDs. [12] We found that recombinant protein (HisGB1) [12] conjugatedQ Ds could bind monoclonala nti-HER2 (human epidermal growth factor 2) [13] 52 antibody through the B1 domain present at the QD surface. [14] In this work, we appliedt his conjugation strategy for the preparation of avisible and NIR dual-color-emitting fluorescent probe with antibody-binding ability.
Herein, we present fluorescent,r ecombinant protein (Hi-sEGFP-GB1)-conjugated, NIR-emitting quantum dots (QDs) that have the ability to bind immunoglobulin G( IgG) on the QD surface. We show that ah istidine-tagged protein (HisEGFP-GB1) easily binds to the surface of the NIR-emitting CdSeTe/ CdS QDs to form HisEGFP-GB1-conjugated QDs. These recombinant-protein-conjugated QDs allow visible and NIR dualcolor molecular imaging to be achieved at the same time. We demonstrate the capability of the dual-color-emitting QD probe forf luorescencem olecular imaging of breast tumor cells in vitro and in vivo.
Results and Discussion

Design and synthesis
To achieve in vitro and in vivo fluorescencem olecular imaging by using single probes, visible-a nd NIR-emitting dual-color probesa re desirable. We synthesized fluorescentr ecombinant protein (HisEGFP-GB1)-conjugated, NIR-emitting CdSeTe/CdS QDs (GSH-QDs), [12] in which the recombinant protein consists of fluorescent protein (EGFP) and the immunoglobulin binding domain (B1) of protein G( Scheme 1). As the recombinant protein (HisEGFP-GB1) has aH is 6 tag at its Nterminus, this protein directly binds to the surface of aC dS layer of CdSeTe/CdS (core-shell) QDs. [12] Given that histidine has high binding affinity for Zn 2 + ions as wella sC d 2 + ions, [15] histidine-tagged proteins also can bind to aZ nS layer of CdSe/ZnS (core-shell) QDs. [12] HisEGFP-GB1-conjugatedQ Ds (GB1-EGFP-QDs)w ere easily prepared only by mixingG SH-QDs and HisEGFP-GB1 protein in an aqueous solution.G B1-EGFP-QDsc an bind the IgG antibodyt hrough the B1 domain of the recombinantp rotein present at the QD surface. In this study,w eu sed the anti-HER2 [13] antibody for molecular imaging of HER2 overexpressing breast tumor cells in vitro and in vivo.
The binding of HisEGFP-GB1 to GSH-QDs was confirmed by agarose gel electrophoresis. Figure 1s hows the agaroseg el electrophoresis of GSH-QDs in the absence and presence of Hi-sEGFP-GB1 (37.4 kDa) and EGFP-GB1 (35.3 kDa) with no histidine tags (Figures S1 and S2 in the Supporting Information). Gel electrophoresis shows that the mobilityo fG SH-QDs is significantly lowered by the addition of HisEGFP-GB1, whereas the mobility of GSH-QDs is not changed by the addition of EGFP-GB1.T his result shows that HisEGFP-GB1 can bind to GSH-QDs through its histidine tags, whereas EGFP-GB1 cannot bind to the QDs because of the absence of histidine tags. Notably,E GFP emission (at l = 515 nm) in the mixture of GSH-QDs and HisEGFP-GB1 is very weak relative to that in the mixture of GSH-QDs and EGFP-GB1. This finding indicates the FRET [16] from EGFP to the QDs in the HisEGFP-GB1-conjugated QDs (GB1-EGFP-QDs).
Fluorescence spectra,size, and stability of the QD probes
The fluorescences pectrum of GB1-EGFP-QDs shows dual-color (visible and NIR) emission resulting from EGFP and the QDs (Figure 2A ). To confirm FRET from EGFP to the QDs, we examined the NIR fluorescencei ntensity of GSH-QDs in the absence Scheme 1. Schematicrepresentation for preparing fluorescent, recombinant protein (HisEGFP-GB1)-conjugated QDs (GB1-EGFP-QDs) from glutathionecapped CdSeTe/CdSQ Ds (GSH-QDs), and antibody conjugation to GB1-EGFP-QDsb yt he B1 domainatt he QD surface. . ChemBioChem 2019, 20,568 -575 www.chembiochem.org and presence of HisEGFP-GB1. The NIR fluorescenceo fG SH-QDs increased by af actor of 30 %i nt he presenceo fH isEGFP-GB1 ( Figure 2B ). In addition, we observed that the fluorescence lifetime (t)f or EGFP fluorescence in HisEGFP-GB1 is significantly decreased by the addition of GSH-QDs ( Figure 2C ). The increase in the NIR emission of the QDs and the decrease in the lifetimeo fE GFPe mission in GB1-EGFP-QDs show FRET from EGFP (donor) to the QDs (acceptor) in GB1-EGFP-QDs. [17] For comparison, we examined the fluorescences pectra of GSH-QDs in the absence and presenceo fE GFP-GB1 and its EGFP fluorescenced ecay in the absence and presence of GSH-QDs. Compared to HisEGFP-GB1, the addition of EGFP-GB1t o GSH-QDs results in almost no differencei nt he NIR fluorescence intensity of GSH-QDs (Figure S3 A). The fluorescence decay curve of EGFP in EGFP-GB1 does not change upon the addition of GSH-QDs (Figure S3 B) . These results indicatet hat EGFP-GB1p rotein does not bind to GSH-QDs and that FRET cannotoccur in the mixture of GSH-QDs and EGFP-GB1.
The FRET efficiency from EGFP to the QDs can be calculated from both the fluorescencel ifetimes and the fluorescencei ntensity of ad onor (EGFP) [Eqs.
(1) and (2)]:
in which t D and t DA are the lifetimes of the donor in the absence and presence of the acceptor and F D and F DA are the relative fluorescencei ntensities of the donori nt he absence and presence of the acceptor. [16] From the fluorescencel ifetimes ( Figure 2C )a nd relative fluorescencei ntensity ( Figure 2D )o f EGFP emission, FRET efficiency wasc alculated to be 75 and 90 %, respectively.T his high FRET efficiency may come from direct binding of HisEGFP-GB1protein to the surface of the QDs by its histidine tags. For application of the fluorescent probes for in vivo imaging, their hydrodynamic size and stabilitya re important issues. This is because the hydrodynamic size of the probes affects the efficacy of their clearance from the body.I tw as previously shown that ah ydrodynamic size larger than 15 nm prevented renal clearance. [18] Transmission electron microscopy showed that GB1-EGFP-QDs are monodispersed particles, and the core size of the QDs is (4.1 AE 0.8) nm ( Figure S4 ). From dynamic light scattering measurements, the hydrodynamic sizes of GB1-EGFP-QDs andG SH-QDs were determined to be approximately 9a nd 5nm, respectively (FigureS5A); this is indicative of renal clearance of the QDs from the body.T he values of the zeta potentialf or GB1-EGFP-QDs and GSH-QDs are also showni n Figure S5 B.
The stability of these probes in aqueous solutionsw as checked at different pH values. Figure 3s hows the time course of fluorescencei ntensity of GB1-EGFP-QDs at pH 4, 6.8, 7.4, and 9 . Under basic anda cidic conditions (pH 4, 6.8, and 9), the fluorescencei ntensity of GB1-EGFP-QDs decreases with time, whereas their fluorescence intensity under physiological pH conditions (phosphate-buffered saline, PBS, pH 7.4) is stable within 3h.A tp H4,t he fluorescence intensity of GB1-EGFP-QDs immediatelyd iminishes by aggregation of the QDs. We also checked the fluorescencei ntensity of GB1-EGFP-QDs in a cell-culture medium( Figure S6 ). Theirf luorescencei ntensity is very stable in the culture medium over 3h,s howing the capability of GB1-EGFP-QDsf or cellular imaging.
Antibody binding ability
To confirm the binding ability of HisEGFP-GB1 protein for antibody,w eperformed agarose gele lectrophoresis. The mobility ChemBioChem 2019, 20,568 -575 www.chembiochem.org of HisEGFP-GB1 significantly decreases by the addition of anti-HER2 antibody (Ab), whereas the mobility of HisEGFPw ith no B1 domain does not change upon the addition of Ab (Figure 4A ). This result shows the bindinga bility of HisEGFP-GB1 toward the antibody.
Next, we examined the antibody-binding ability of HisEGFP-GB1-conjugated QDs (GB1-EGFP-QDs) by agarose gel electrophoresis for the mixture of GSH-QDs and HisEGFP-GB1 (1:30) and the mixture of GSH-QDs and HisEGFP (1:30) in the absence and presence of Ab ( Figure 4B ). The mobility of GSH-QDs is lowered by the addition of both HisEGFP-GB1 and HisEGFP (lanes 2a nd 5i nF igure 4B). This shows the binding of these proteins to the surface of GSH-QDs through the histidine tags to form HisEGFP-GB1-conjugated QDs (GB1-EGFP-QDs) and His-EGFP-conjugatedQ Ds (EGFP-QDs). The successive addition of Ab to GB1-EGFP-QDs or EGFP-QDs gives different results. The mobility of GB1-EGFP-QDs is lowered by the addition of antibody,w hereas the mobility of EGFP-QDs does not change after the addition of Ab (lanes 3a nd 6i nF igure4B). This finding shows the antibody-binding ability for GB1-EGFP-QDs, but not for EGFP-QDs.
To evaluatet he binding affinity of HisEGFP-GB1f or Ab, we examined the effect of Ab on the diffusion time of HisEGFP-GB1 protein by using fluorescencec orrelation spectroscopy (FCS). [19] FCS can measure fluctuationsi nt he fluorescencei ntensity of fluorophores at the single-molecule level and gives the diffusion time of the fluorophores in solution. [20] As shown in Figure 5 , the binding of antibody to HisEGFP-GB1 is confirmed by changes in the FCS curve of HisEGFP-GB1a fter the addition of Ab. Upon increasing the concentration of Ab, the FCS curve shifts to the right side;t his is indicative of an the increasei nt he diffusion time of HisEGFP-GB1 by complexing with Ab. The inset shows ar elationship between the diffusion time of HisEGFP-GB1 and the concentration of Ab. This result shows that the affinity of HisEGFP-GB1 for Ab is very high (nanomolar level),a nd the dissociation constant of Ab conjugates with HisEGFP-GB1 is 12.5 nm.T his value is comparable to the earlier reported value for the dissociation constant of the B1 domain andI gG complex (33 nm). [11] The number of His-EGFP-GB1m olecules that can bind to one particleo fG B1-EGFP-QDs was determined by using size-exclusion liquid chromatography ( Figure 6A ). From ar elationship between the retention times of standard proteins and their molecular weights Figure 6A ), the apparent molecular weights of GSH-QDs and GB1-EGFP-QDs were determined to be 250 and 750 kDa, respectively.A st he molecular weight of HisEGFP-GB1 is 37.4 kDa, the number of HisEGFP-GB1 molecules bound to one particleofGB1-EGFP-QD was estimated to be 13. This finding is comparable to the result of agarose gel electrophoresis for the addition of HisEGFP-GB1 to GSH-QDs ( Figure 6B ).
Cellular imaging
To check the probe activity of anti-HER2 antibody + GB1-EGFP-QDs, we performed fluorescence imaging of human breast tumor (KPL-4) cells, [21] for which the HER2 receptors are overexpressed on the cell membrane. HeLa cells were used as anegative control, as the expression level of HER2 is very low relative to that of KPL-4cells ( Figure S7 ). [22] For cellular imaging, we first added anti-HER2 antibody to KPL-4 cells. The cells were washed with PBS, and then GB1-EGFP-QDs were added. After incubation of the cells with GB1-EGFP-QDs for 10 min, we performed cellular imaging. Figure 7A shows the fluorescence images for HeLa and KPL-4 cells after staining with antibody( humann ormal IgG or anti-HER2 antibody), followed with GB1-EGFP-QDs. Humann ormal IgG was used as an egative antibody.I nt he case of KPL-4 cells, their plasma membranes were strongly stainedb ya nti-HER2 antibodya nd GB1-EGFP-QDs, showingthe intensefluorescence emission of EGFP and the QDs from the membrane. In contrast, HeLa cells were not stainedb ya nti-HER2 antibody + GB1-EGFP-QDs, andt hey showedv ery week emissionf rom EGFP and QDs. This result shows that anti-HER2 antibody + GB1-EGFP-QDs specifically bind to the plasma membrane of HER2overexpressing KPL-4 cells. In contrast,t he incubationo fH eLa and KPL-4c ells with human normalI gG and GB1-EGFP-QDs did not show significant EGFP andQ Df luorescence emission from the plasma membranes.F low cytometric analysis( Figure 7B ) also confirmed the specific binding of the anti-HER2 antibody and GB1-EGFP-QDst oKPL-4cells.
The effect of HisEGFP-GB1 and GB1-EGFP-QDs on cell viability was checked by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay ( Figure S8) . Although His-EGFP-GB1 did not show cytotoxicity,G B1-EGFP-QDs showed dose-dependentcytotoxicity in HeLa cells.
Whole-bodyimaging
Finally,w ea chieved in vivo fluorescence imaging of breasttumor-bearing mice by using anti-HER2 antibody and GB1-EGFP-QDs. Breast-tumor ( % 10 mm in diameter) bearing mice were prepared by transplantation of as uspension of KPL-4 cells ( % 10 7 cells) to the dorsal skins of nude mice. First, we injected GB1-EGFP-QDs to breast-tumor-bearingm ice to examine whether the QDs could accumulate in the tumor tissue by the enhanced permeability and retention (EPR) effect. [23] Althoughi ntense NIR fluorescencee mission of the QDs was observed from al iver,s ignificant NIR emission was not observed from ab reast tumor ( Figure S9 ). Most of the QDs were excreted from the body 1day after postinjection of the QDs (Figure S9) . Figure 7 . A) Fluorescence imageso fH eLa and KPL-4 cells that were incubated by antibody,followed by GB1-EGFP-QDs. Left) Fluorescence images of EGFP (green)and Hoechst 33342( blue). Right) Fluorescence images of QDs (purple) and Hoechst 33342(blue). B) Flow cytometric analysis of HeLa and KPL-4 cells treatedwith normal human IgG + GB1-EGFP-QDs (green)ora nti-HER2 antibody + GB1-EGFP-QDs (red). ChemBioChem 2019, 20,568 -575 www.chembiochem.org Next, we injected the mixtureo fa nti-HER2 antibody + GB1-EGFP-QDs to breast-tumor-bearing mice to check the specific accumulation of QDs in the breast tumor.A t2 2hpostinjection of the antibody-QD conjugates, we observed intense NIR emission from the breastt umor as well as al iver ( Figure 8A) . After 48 h, we observedt hat most of the QDs were accumulated in the tumor.T oc onfirm the specific accumulation of QDs in the breast tumor,w ea lso performed ex vivo fluorescence imaging for isolated tumor and major organs ( Figure 8B ). We observed intense NIR fluorescencee mission of the QDs from the isolated tumor (top image in Figure 8B ). Visible( EGFP) fluorescence was also observed from the tumor (bottom image in Figure 8B) . Notably,t he EGFP fluorescencee missions from al iver and spleen were much weaker than QD emission ( Figure 8B ). This may have resulted from protease-mediated degradation of EGFP protein in liver and spleen tissue. [24] By using anti-HER2 antibody and GB1-EGFP-QDs, we could achieve visible and NIR dual-color fluorescencei maging to confirm the specific tumor accumulation of the QD probe.
Conclusion
In summary,w epresented af luorescent, recombinant protein (HisEGFP-GB1)-conjugated, NIR-emittingQ Dp robe for in vitro and in vivom olecular imaging. The presentp robe (GB1-EGFP-QDs) showeddual-color (visible and NIR) fluorescencee mission resultingf rom EGFPa nd the QDs. Thisd ual-colorp robe has the ability to bind antibody through the immunoglobulin binding (B1) domain present at the QD surface. Thus, the probe could be used for fluorescencem olecular imaging at the cellular and whole-body levels.A st he preparation of antibody( IgG) conjugates with GB1-EGFP-QDs is facile and rapid, this dualcolor probe should be very useful for av ariety of fluorescent molecular imaging in vitro and in vivo.
Experimental Section
Materials:S elenium (Se, powder,9 9. 999 %) and tellurium (Te, shot, 1-2 mm, 99.99 %) were purchased from Sigma-Aldrich. Cadmium 2,4-pentanedionate was purchased from Alfa Aesar. n-Octadecylphosphonic acid (ODPA) was purchased from PCI. Trioctylphosphine oxide (TOPO) trioctylphosphine (TOP),t ributylphosphine (TBP), and hexadecylamine (HDA, 90 %) were purchased from To kyo Chemical Industry (Japan). Sulfur (S, crystalline, 99.9999 %), glutathione (GSH, reduced form), and potassium tert-butoxide were purchased from Wako Chemicals (Japan). Anti-HER2 monoclonal antibody (Ab) was purchased from Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). Other organic solvents were of analytical-reagent grades.
Synthesis of GSH-QDs:T he synthesis of GSH-QDs is reported elsewhere. [14] At ypical procedure is as follows. AS e-Tes tock solution was prepared by dissolving Se (24 mg, 0.3 mmol) and Te (13 mg, 0.1 mmol) in TBP (1 mL) at room temperature. AC d-S stock solution was prepared by adding sulfur (40 mg, 1.25 mmol) to TBP (10 mL). After sulfur was completely dissolved, as ulfur solution was cooled to room temperature. Then, cadmium 2,4-pentanedionate (388 mg, 1.25 mmol) was added to the sulfur solution in TBP, and the solution was warmed at 100 8Ct od issolve cadmium 2,4pentanedionate. The Cd-S stock solution was stored under argon at room temperature.
Am ixture of cadmium 2,4-pentanedionate (150 mg, 0.48 mmol), ODPA( 300 mg, 0.90 mmol), TOPO (1 g), HDA (3 g), and TOP (0.5 mL) was loaded into a2 5mL, three-necked flask and heated to 330 8Cu nder argon. At this temperature, aS e-Tes tock solution (0.5 mL) was quickly injected by using as yringe, and this caused an immediate color change in the solution from colorless to brown. By monitoring the QD fluorescence spectra, the formation of QDs (l % 800 nm emission) was checked. When the desired QDs were formed, the solution was cooled to 60 8Ca nd chloroform (10 mL) was added. The QDs were precipitated by the addition of methanol, and the QDs precipitate was separated by centrifugation. The resulting QDs precipitate and HDA (3 g) were loaded into a2 5mL, three-necked flask and heated to 250 8C. At this temperature, the formation of the CdS shell was performed. The addition ChemBioChem 2019, 20,568 -575 www.chembiochem.org of aC d-S stock solution (0.25 mL) resulted in the formation of CdSeTe/CdS QDs that emit at l % 850 nm. Then, the QD solution was cooled to 80 8Ca nd chloroform (10 mL) was added. The QDs were precipitated by the addition of methanol and were separated by centrifugation (1000 g,1 0min). To remove excess amounts of TOPO and HDA, the QDs were dissolved in chloroform again and precipitated by the addition of methanol. This procedure was repeated three times. The resulting QDs were dissolved in chloroform (20 mL) and stored in the dark.
For the GSH coating, an aqueous solution (1 mL) of GSH (100 mg mL À1 )w as slowly added to at etrahydrofuran solution (1 mm,2mL) of CdSeTe/CdS QDs at room temperature under sonication. The QDs precipitate was separated by centrifugation. An aqueous solution of potassium tert-butoxide (20 mg mL À1 ,2mL) was added to the QDs precipitate under stirring. The solution was sonicated for 5min and filtered through a0 .45 mm membrane filter.T he excess amounts of GSH and potassium tert-butoxide were removed by dialysis by using a1 0mm Na 2 CO 3 aqueous solution. The resulting GSH-QDs was preserved at 4 8C.
Protein synthesis:F or the HisEGFP-GB1 and HisEGFP proteins, the EGFP sequence was amplified by PCR from pEGFP-C1 plasmid (Clontech). The protein GB 1s equence was amplified by PCR from pET His 6 protein GT EV LIC cloning vector (2P-T), Addgene plasmid 29 713. The PCR fragments were fused with pRSET plasmid (Ther-moFisher) by using the InFusion HD cloning kit (Clontech). Next, The pRSET-EGFP-GB1 plasmid was transformed into E. coli KRX competent cells (Promega). For large-scale cultures, the transformed cells were grown in lysogeny broth (LB;2 00 mL) with ampicillin (100 mgmL À1 )a t3 78Co nas haking table, until the OD 600 approached 0.6. To induce production of the targeted protein, isopropyl-d-1-thiogalactopyranoside (0.2 mm)a nd l-rhamnose (0.1 %) were added to the LB medium, and the cells were incubated with shaking gently for 16 ha t1 88C. The cells were collected by centrifugation at 5000 g for 10 min. The pellet was resuspended in binding buffer (5 mL, 50 mm Tris·HCl, 500 mm NaCl, 20 mm imidazole, pH 8.0) . Before cell lysis, complete EDTA-free protease inhibitor cocktail tablets (1 ,R oche) were added as ap rotease inhibitor. The solution was sonicated on ice by using 10 sb ursts at middle intensity with a1 0scooling period between each burst. The lysate was clarified by centrifugation at 20 000 g for 30 min to eliminate cell debris. The next step was purification by Ni Sepharose 6F ast Flow (GE Healthcare). Sepharose medium equilibrated with binding buffer (3 mL) was added to each 5mLo fl ysed sample, and the samples were incubated with gentle agitation at room temperature for 5min. After the solution was transferred to an empty column, the column was washed with five column volumes of binding buffer.L astly,t he HisEGFP-GB1 and HisEGFP proteins were drained from the column by the addition of elution buffer (50 mm Tris·HCl, 500 mm NaCl, 500 mm imidazole, pH 8.0). The eluted fractions were further purified by gel filtration column (PD-10 columns, GE Healthcare).
For the EGFP-GB1 protein, first the GST-EGFP-GB1 protein was expressed and lysed following the protocol previously reported by Sasaki et al. [5c] The lysate was clarified by centrifugation at 20 000 g for 30 min to eliminate cell debris. The next step was purification by Glutathione Sepharose 4B (GE Healthcare). Sepharose medium equilibrated with PBS (2 mL) was added to each 5mLo fl ysed sample, and the samples were incubated with gentle agitation at 4 8Cf or 60 min. The Sepharose medium was then washed twice with Turbo3C Protease buffer,f ollowed by digestion of the GST-tag by overnight incubation at 4 8Cw ith 80 Uo fT urbo3C Protease (Accelagen) in Turbo3C Protease buffer.T he EGFP-GB1 protein was further purified by gel filtration column (PD-10 columns, GE Healthcare).
Preparation of HisEGFP-GB1-conjugated QDs (GB1-EGFP-QDs):
HisEGFP-GB1 (1 mg mL À1 ,P BS, 200 mL) was added to an aqueous solution of GSH-QDs (1 mm,1 0mm Na 2 CO 3 solution, 0.4 mL). Then, the excess amount of HisEGFP-GB1 protein was removed by using dialysis or ultrafiltration with a100 kDa membrane filter.
Fluorescence measurements:T he fluorescence spectra of the QDs were measured with ap hotonic-multichannel analyzer (C10027, Hamamatsu Photonics, Japan) with a150 Wxenon lamp (excitation light source at l = 488 nm). Fluorescence autocorrelation curves of the QDs were measured by using ac ompact FCS system (C9413-01MOD, Hamamatsu Photonics, Japan). For determination of the concentration of GSH-QDs, we measured the number of QD particles in 20 mLo ft he QD solution by using FCS and estimated its concentration by using as olution of rhodamine 6G (20 nm)a sa reference. For all measurements, the pH of the aqueous solution of the QDs was set to 7.4 with PBS buffer.F luorescence decay curves for EGFP were measured by excitation at l = 480 nm by using time-correlated single-photon counting (Horiba Fluoro Cube).
Size-exclusion HPLC:S ize-exclusion column chromatography with aH PLC system (ELITE LaChrom, HITACHI) was performed by using aT SK-gel G4000SW column (7.8 mm 30 cm, TOSOH). The mobile phase was 10 mm PBS (pH 7.2-7.4), and the flow rate was adjusted to 1mLmin À1 .S tandard proteins of thyroglobulin (670 kDa), ferritin (450 kDa), bovine serum albumin (BSA, 66 kDa), and HisEGFP (30.8 kDa) were measured to draw ac alibration curve. The HPLC chromatographs of GSH-QDs and HisEGFP-GB1-conjugated QDs were obtained by monitoring absorption at l = 488 nm.
Agarose gel electrophoresis:T hese proteins were run on 1% agarose gel in Tris·acetate buffer (pH 8.0), 100 Vf or 15 min. Fluorescence emissions of the QDs and EGFP were monitored at l = 830 and 515 nm, respectively.
Cellular imaging:K PL-4 and HeLa cells were seeded to collagencoated glass-bottomed dishes (D11134 H, Matsunami 35 mm) and were incubated in Dulbecco's Modified Eagle Medium (DMEM) with 10 %f etal bovine serum (FBS) for overnight at 37 8C. Anti-HER2 antibody or normal human IgG (0.1 mm)a nd Hoechst 33342 (5 mgmL À1 )w ere added to the cells, which were incubated for 20 min at 37 8C. Then, the cells were washed with PBS (3 ). Next, the complex of GSH-QDs (5 nm)a nd HisEGFP-GB1(0.1 mm)w as added, and the cells were incubated for 10 min at 37 8C. Then, the cells were washed with PBS (3 )a nd filled with Opti-MEM (Life Te chnologies). Fluorescence images were acquired with af luorescence microscope (BZ-X700, Keyence Corp.,J apan) by using an objective lens Nikon PlanApo l 40 .T he excitation and emission filters were l ex = (470 AE 20) nm and l em = (525 AE 25) nm (for EGFP signal), l ex = (560 AE 20) nm and l em = 590 nm long pass (QD830), and l ex = (360 AE 20) nm and l em = (460 AE 25) nm (Hoechst).
Flow cytometric analysis:A fter cellular imaging, the cells were collected by trypsinization and were resuspended in PBS. Then, the cell suspension was analyzed by af low cytometer (MACSQuant Analyzer,M iltenyi Biotec Inc.). Fluorescence of EGFP was collected through aF L2 (FITC) filter [l ex = 488 nm, l em = (525 AE 25) nm].F luorescence of the QDs was collected through aF L7 (APC-Cy7) filter (l ex = 635 nm, l em = 750 nm long pass).
In vivo imaging:Asuspension of KPL-4 cells (0.5 10 7 cells per mouse) was transplanted to the dorsal skins of five-week-old female BALB/c nu/nu mice (Japan SLC, Inc.). After several weeks, we selected am ouse bearing at umor less than 10 mm in diameter for imaging. An aliquot (200 mL) of an aqueous solution (500 mgo f Ab + 0.5 nmol of HisEGFPGB1-QDs in Na 2 CO 3 (1 mL, 10 mm)w as injected into ax enografted mouse through at ail vein. NIR fluorescence images [l ex = 650 nm, l em = (830 AE 20) nm] were taken by using an in vivo fluorescence imaging system (Bruker,M SF XP RO). Exposure time of the excitation light was 30 s. All animal experiments were approved by the RIKEN Animal Care and Use Committee.
